Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 1/2000

01-12-2001 | Paper Report

Dual HER-2/EGFR tyrosine kinase inhibitors

Author: Fatima Cardoso

Published in: Breast Cancer Research | Issue 1/2000

Login to get access

Excerpt

Cancer therapy has been changing from conventional nonspecific treatments to selective targeted therapies. EGFR and HER-2 are co-expressed in a variety of tumour types. The available tyrosine kinase inhibitors are moving to phase II and phase III clinical trials, with a favourable toxicity profile. There is a biological rational for attempting to block the growth factors signalling pathways at several sites simultaneously. The use of a dual inhibitor of both EGFR and HER-2 could provide a therapeutic benefit to a broad patient population. …
Literature
1.
Rusnak DW, Affleck K, Cockerill SG, Stubberfield C, Harris R, Page M, Smith KJ, Guntrip SB, Carter MC, Shaw RJ, Jowett A, Stables J, Topley P, Wood ER, Brignola PS, Kadwell SH, Reep BR, Mullin RJ, Alligood KJ, Keith BR, Crosby RM, Murray DM, Knight WB, Gilmer TM, Lackey K: The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. Cancer Res. 2001, 61: 7196-7203.PubMed
Metadata
Title
Dual HER-2/EGFR tyrosine kinase inhibitors
Author
Fatima Cardoso
Publication date
01-12-2001
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2000
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr-2001-72700

Other articles of this Issue 1/2000

Breast Cancer Research 1/2000 Go to the issue

Paper Report

Prognosis and treatment of small breast carcinomas

Paper Report

Her-2/neu expression in primary breast cancer and its lymph node metastases

Paper Report

Nuclear cytometric changes in breast carcinogenesis

Review

Breast imaging technology: Recent advances in imaging endogenous or transferred gene expression utilizing radionuclide technologies in living subjects: applications to breast cancer

Paper Report

HOXA5 regulation of p53 in breast tumours

Paper Report

Tissue microarray validation
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits